Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Hiromi Gotou"'
Autor:
Hiromi, Rakugi, Kazuomi, Kario, Masako, Yamaguchi, Takayoshi, Sasajima, Hiromi, Gotou, Jack, Zhang
Publikováno v:
Hypertension Research. 45:824-833
This phase III study assessed the efficacy and safety of sacubitril/valsartan compared with those of olmesartan in Japanese patients with essential hypertension. Patients (n = 1161, aged ≥20 years) with mild to moderate hypertension (mean sitting s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::128bb052c8da58b33d2e7cab1dee9ac2
https://doi.org/10.1038/s41440-021-00819-7
https://doi.org/10.1038/s41440-021-00819-7
Autor:
Koji Ono, Katsumi Hirose, Takanori Ohnishi, Yoshitaka Narita, Shin-Ichi Miyatake, Kato Takahiro, Hiromi Gotou, Hiroki Tanaka, Shinji Kawabata, Yoshihiro Takai, Minoru Suzuki
Publikováno v:
Journal of Clinical Oncology. 38:2536-2536
2536 Background: Boron neutron capture therapy (BNCT) is tumor-selective particle radiation and theoretically efficacious especially for tumors with infiltrative nature, such as glioblastoma (GBM). The aim of this study is to assess safety and effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e51819ec7cbdf7600cdc8f5854208a32
https://doi.org/10.1200/jco.2020.38.15_suppl.2536
https://doi.org/10.1200/jco.2020.38.15_suppl.2536
Autor:
Toru Aoyama, Masatoshi Fukunishi, Hiromi Gotou, Etsuya Tamura, Jun Agata, Asami Satou, Ryouji Takano
Publikováno v:
Choonpa Igaku. 37:141-147
症例は63歳，男性．心筋梗塞にて冠動脈形成術の既往あり．早朝，強い前胸部痛を自覚し当院に緊急搬送された．来院時心電図ではST変化は明らかではないが，以前と比べ右脚ブロックへ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a4111de754017166a2af1ef89790d0a
https://doi.org/10.3179/jjmu.37.141
https://doi.org/10.3179/jjmu.37.141
Autor:
Kazuo Watanabe, Zenichiro Watanabe, Kenji Izaki, Yasuhiro Kikuchi, Sinya Tamura, Hiromi Gotou, Kazusige Maeno, Jin-ichi Koizumi, Sadayosi Watanabe
Publikováno v:
Nosotchu. 30:478-483
（目的）急性期破裂脳動脈瘤手術において脳虚血は，頻度の高い合併症であるが，今回周術期の脳塞栓の発生頻度を明らかにし，検討を加えたので報告する． （対象，方法）2004年から20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3f1ad21e4d29d11441d4bf9635a3f24
https://doi.org/10.3995/jstroke.30.478
https://doi.org/10.3995/jstroke.30.478
Publikováno v:
Choonpa Igaku. 35:437-441
大動脈縮窄症は大動脈弓より遠位で動脈管接合部に狭窄を生じる先天性疾患である．心奇形を伴う複合型と動脈管が閉鎖し心奇形を合併しない単純型に大別され，成人例では薬物抵抗性
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0f13047b5f7cf975e0303c5f6378cf8
https://doi.org/10.3179/jjmu.35.437
https://doi.org/10.3179/jjmu.35.437
Publikováno v:
J Clin Hypertens (Greenwich)
The safety of LCZ696, a novel angiotensin receptor-neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8-week, multicenter, open-label study. Thirty-five Japanese patients with either office systolic bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a050662efde797408044af6e99e54d3e
https://europepmc.org/articles/PMC8032009/
https://europepmc.org/articles/PMC8032009/
Autor:
Yoshihisa Abo, Deborah L. Keefe, Hiromi Gotou, Toshio Kushiro, Hiroshige Itakura, Shinji Terao
Publikováno v:
Hypertension Research. 29:997-1005
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17690df16299849c644abff017446fc8
https://doi.org/10.1291/hypres.29.997
https://doi.org/10.1291/hypres.29.997
Publikováno v:
Hypertension. 64
Objective: To evaluate the efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) vs olmesartan in Japanese patients with systolic hypertension (SH). Methods: Patients aged ≥20 yrs with mean sitting (ms) SB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c825078453e6552a098d34daa1e7ffc
https://doi.org/10.1161/hyp.64.suppl_1.474
https://doi.org/10.1161/hyp.64.suppl_1.474
Autor:
Sadayoshi Ito, Mizuki Akahori, Hiromi Gotou, Alan Charney, Yuko Tamaki, Jack Zhang, Naoko Okino, Minoru Satoh
Publikováno v:
Hypertension Research
This 8-week, multi-center, open-label study assessed the safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Patients (n=32) with mean sitting systol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b485511e67df49aeaf6f5d4a5fef943
https://pubmed.ncbi.nlm.nih.gov/25693859
https://pubmed.ncbi.nlm.nih.gov/25693859
Autor:
Jack Zhang, Fu-Tien Chiang, Ying Zhang, Ningling Sun, Martin Lefkowitz, Kazuomi Kario, Akiko Inubushi-Molessa, Ouppatham Supasyndh, Sang Hong Baek, Hiromi Gotou
Publikováno v:
Hypertension (Dallas, Tex. : 1979). 63(4)
Abstract— LCZ696 (Japanese adopted name: sucabitril valsartan sodium hydrate), a first-in-class angiotensin receptor neprilysin inhibitor, concomitantly inhibits neprilysin and blocks angiotensin type 1 receptor. This randomized, double-blind, plac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfa24b4c6aaf56f508e38d486d404635
https://pubmed.ncbi.nlm.nih.gov/24446062
https://pubmed.ncbi.nlm.nih.gov/24446062